Agentix Corp. cash flow statement AGTX

Annual Quarterly

In fiscal 2026, which ended Mar 31, 2026, Agentix Corp. used $108,529 of cash from operations, up 13.2% from the year before.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.

Line	FY 2027 Jun 30, 2026	FY 2026 Mar 31, 2026	FY 2025 Mar 31, 2025	FY 2024 Mar 31, 2024	FY 2023 Mar 31, 2023	FY 2022 Aug 31, 2021	FY 2019 Aug 31, 2019	FY 2018 Aug 31, 2018	FY 2017 Aug 31, 2017	FY 2016 Aug 31, 2016	FY 2015 Aug 31, 2015
Operating
Depreciation and amortization	—	—	—	—	—	—	0 -47.0%	0 +0.0%	0 +0.0%	0 +33.3%	0
Operating cash flow	-0 +93.1%	-0 +13.2%	-0 -13.3%	-0 -24.7%	-0 +79.0%	-0	-0 -20.3%	-0 +32.5%	-0 -507.6%	-0 +93.3%	-0
Investing
Investing cash flow	0	0	0	0	0	0	—	—	-0	—	—
Financing
Financing cash flow	0 -79.6%	0 +10.4%	0 +7.5%	0 -7.0%	0 -44.4%	0	0 +20.0%	0 -43.8%	0 +36.3%	—	0
Change in cash
Effect of exchange rate	-0	-0 -124.4%	0 +98.5%	0	—	—	—	—	—	—	—
Net change in cash	-0 +6.1%	-0 -80.1%	-0 +64.7%	-0 -147.7%	0 +105.1%	-0	—	—	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: AGTX (OTC)
Fiscal year ends: March 31
Incorporated in: NV
Headquarters: Dana Point, CA
SEC filer status: Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK: 1603345
Former names: FairWind Energy Inc. (until Jun 27, 2019)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.